Purpose: Detecting gene mutations by two competing biomarkers, circulating tumor cells (CTCs) and ctDNA has gradually paved a new diagnostic avenue for personalized medicine. We performed a comprehensive analysis to compare the diagnostic value of CTCs and ctDNA for gene mutations in lung cancer. Methods: Publications were electronically searched in PubMed, Embase, and Web of Science as of July 2018. Pooled sensitivity, specificity, and AUC, each with a 95% CI, were yielded. Subgroup analyses and sensitivity analyses were conducted. Quality assessment of included studies was also performed. Results: From 4,283 candidate articles, we identified 47 articles with a total of 7,244 patients for qualitative review and meta-analysis. When detecting EGFR, the CTC and ctDNA groups had pooled sensitivity of 75.4% (95% CI 0.683-0.817) and 67.1% (95% CI 0.647-0.695), respectively. When testing KRAS, pooled sensitivity was 38.7% (95% CI 0.266-0.519) in the CTC group and 65.1% (95% CI 0.558-0.736) in the ctDNA group. The diagnostic performance of ctDNA in testing ALK and BRAF was also evaluated. Heterogeneity among the 47 articles was acceptable. Conclusion: ctDNA might be a more promising biomarker with equivalent performance to CTCs when detecting EGFR and its detailed subtypes, and superior diagnostic capacity when testing KRAS and ALK. In addition, the diagnostic performance of ctDNA and CTCs depends on the detection methods greatly, and this warrants further studies to explore more sensitive methods.
Introduction
Lung cancer has the highest incidence and mortality among cancer cases worldwide, with 2.1 million new lung cancer cases and 1.8 million lung cancer deaths in 2018. 1 Accumulating evidence confirms that driven gene mutations play a critical role in the oncogenesis, personalized treatment, and prognosis assessment of lung cancer.
inclusion and exclusion criteria
Studies meeting all the following criteria were included: randomized controlled trials, cross-sectional studies, or cohort studies; focused on lung cancer patients; analyzed diagnostic value of CTCs or ctDNA for gene mutations; used tissue biopsy as the reference standard. Studies were excluded if they met one of the following criteria: reviews, letters, replies, case reports, conference abstracts, or animal experiments; articles not written in English; articles lacking essential information. Any disagreements were discussed.
Quality assessment
Two independent reviewers used RevMan version 5.3 to evaluate the quality of studies included based on the Quality Assessment of Diagnostic Accuracy Studies 2 tool. 8 Questions, including patient selection, index test, reference standard, and flow and timing, would be judged as "yes", "unclear", or "no" for each of the included studies.
Data extraction and management
Two independent authors extracted data: basic data (first author, publication year, countries/regions, number of patients, age, sex, blood volume, isolation methods, extraction methods, detection methods, and others) and diagnostic data (true positive, false positive, true negative and false negative). Disagreements were resolved by consensus.
statistical analysis
Meta-Disc version 1.4 was used to calculate pooled sensitivity, pooled specificity, AUC, positive-likelihood ratio and negative-likelihood ratio, each with a 95% CI. Forest plots and a summary receiver-operating characteristic (sROC) curves were plotted to present the results visually. Both threshold effect and nonthreshold effect were assessed to find the potential source of heterogeneity. If the P-value of the Spearman correlation coefficient was ,0.05, a threshold effect would exist. When the P-value of Cochran's Q test was ,0.10, a nonthreshold effect would be identified. Subgroup analyses were performed one subtypes of EGFR mutations, detection methods of liquid biopsy, and consistency of detection methods between liquid biopsy and tissue biopsy. Sensitivity analyses were also carried out to test the robustness of the main results by removing low-quality studies one by one. Quantitative evaluation of heterogeneity was evaluated by calculating I 2 , in accordance with the Cochrane Collaboration. 
Results

study characteristics
A total of 47 of 4,283 studies were included in our analysis: nine [10] [11] [12] [13] [14] [15] [16] [17] [18] in the CTC group and 42 11, 13, 16, 17, in the ctDNA group (four 11, 13, 16, 17 studies were in both groups; Figure 1 ). Detected gene mutations in lung cancer were mainly in EGFR, KRAS, ALK, and BRAF. The volume of blood samples varied from 5.9 mL to 20.0 mL in the CTC group, and 1.5 mL to 20 mL in the ctDNA group. Detection methods for gene mutations were mainly sequencing and PCR in either liquid biopsy or tissue biopsy. The main characteristics of the CTC group and ctDNA group are shown in Tables 1 and 2 , respectively.
risk of bias
In the CTC group, four studies were identified as low risk and one had unclear risk for the patient selection. Altogether, six publications were assessed as high risk and two had low risk on the index test. Low risk for reference standard was identified in all articles in this group. Four articles reported detailed information about flow and timing, assessed as low risk in this term. A total of four of nine, two of nine, and nine submit your manuscript | www.dovepress.com
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lyu et al of nine articles had low concern regarding patient selection, index test, and reference standard, respectively. In the ctDNA group, 23 studies were assessed as low risk on patient selection, while two had unclear risk. There were 18 of 42 and 35 of 42 studies with low risk on the index test and reference standard, respectively. For flow and timing, 17 trials had low risk and the rest had high risk. A total of 23 of 42, 18 of 42, and 37 of 42 trials were identified as low concern for patient selection, index test, and reference standard, respectively. The risk of bias of the included studies is shown in Figure 2 . Abbreviations: CTC, circulating tumor cell; ADC, adenocarcinoma; NA, not available; HRM, high-resolution melting; FFPE, formalin-fixed, paraffin-embedded; dd, droplet digital; RT, reverse transcription; ARMS, amplification-refractory mutation system; ngs, next-generation sequencing; ctDna, circulating tumor Dna.
87.7% (95% CI 0-1.000) in the ctDNA group respectively. For ALK, only an sROC curve was plotted in ctDNA group, due to the threshold effect, and the ctDNA group had an AUC of 99.4% (95% CI 0.953-1.000). Summary plots of the CTC and ctDNA groups are shown in Figures 4 and 5, respectively.
subgroup analyses
Although we did not find a nonthreshold effect in the CTC group, we still performed subgroup analyses to identify potential influencing factors of CTCs when detecting different gene mutations.
subtypes of EGFR mutations
Seven subtypes of EGFR mutations -Del19, L858R, T790M, L861Q, E20ins, G719X, and S768I -were taken into consideration. For Del19, three and 18 studies were included in the CTC group and ctDNA groups, respectively. The CTC group and ctDNA group had summary sensitivity of 75.9% (95% CI 0. Notes: *in both the cTc and ctDna groups, with cTc and ctDna data analyzed in two independent articles; **more than ten detection methods, eg, Dna sequencing and fragment length analysis, used in this study; ** 
sensitivity analyses
No significant results were identified in sensitivity analyses.
Discussion
We found that ctDNA and CTCs had similar performance when detecting EGFR and its detailed subtypes. However, ctDNA showed great strength for detecting KRAS and ALK. Subgroup analyses indicated that detection method had a great impact on the diagnostic capacity of ctDNA and CTCs.
CTCs had slightly higher sensitivity than ctDNA when detecting EGFR, which has been supported by some researchers.
14 This may partly be attributed to the low abundance of ctDNA in peripheral blood. Although the level of ctDNA in cancer individuals was much higher than normal, it still accounted for ,1% of cell-free DNA. 57 ctDNA quantity is prone to be only one genome per 5 mL plasma in the early stage of cancer. 58 Therefore, the effective capture of ctDNA is still technically challenging, though Punnoose et al 16 held the opposite opinion that ctDNA might outperform CTCs for EGFR detection. Treatment status may explain this inconsistency to some extent. The proportion of patients receiving treatment in their trial was higher than that in ours, while therapy can decrease CTC counts more effectively and increase the difficulty of detection.
For KRAS, ctDNA showed excellent diagnostic ability. Shen et al 59 conducted a meta-analysis and came to a different conclusion than us. They included two studies that we excluded during literature screening. 60, 61 One did not describe clearly whether they analyzed the value of CTCs or ctDNA, 60 while another extracted RNA from CTCs for detection. 61 Great heterogeneity may exist between these two studies, which might have impacted the final results. Limited articles restricted us in analyzing the value of CTCs for ALK detection. In the ctDNA group, pooled sensitivity and specificity were not yielded, because of a threshold effect, while sROC curves and AUC indicated the high value of ctDNA in testing ALK, in line with other investigators. 62 For BRAF, the value of CTCs was not explored, due to limited studies. ctDNA had low sensitivity, contrary to the results of the following two studies. 63, 64 Guibert et al analyzed only six samples, and did not regard tissue biopsy as the reference standard. 63 Different sample size and reference standard were considered as the reasons for the discrepancy. Thierry et al 64 concentrated on the value of ctDNA in colorectal cancer. Different BRAF mutational load between lung cancer and colorectal cancer may have led to the difference in results.
CTCs and ctDNA showed great variance in performance for different gene mutations and different detection kits, and methods may have contributed also.
subgroup analyses
In view of individual treatment, analyzing detailed EGFRmutation subtypes is critical. Therefore, we focused on the value of CTCs and ctDNA in testing detailed EGFR-mutation subtypes. We found that ctDNA had slightly higher accuracy for del19 and L858R. Different-accuracy detection methods may have an impact. More sensitive methods, including droplet digital PCR and circulating single-molecule amplification and resequencing technology, were used in the ctDNA group. For T790M, which is largely responsible for resistance to first-generation or irreversible tyrosine-kinase inhibitors, 65 CTCs and ctDNA showed similar diagnostic performance. This was consistent with other researchers. 14, 66 Various detection methods had great influence on the accuracy of CTCs and ctDNA; therefore, subgroup analyses based on different detection methods were necessary. In both the CTC and ctDNA groups, sequencing outperformed other detection methods, whether detecting EGFR, KRAS, or BRAF. To our knowledge, the low limit of detection and ability to determine lower mutant-allele frequency confers excellent capacity upon sequencing. 67, 68 Although PCR is a cost-effective technology, it can analyze only limited genomic loci and has a high requirement for mutant-allele frequency. 58 Notably, digital PCR, as distinct from traditional PCR, is considered a very sensitive detection method, 69, 70 and our study also confirmed this (data not shown).
strengths and limitations
Although several meta-analyses were carried out, they focused on the diagnostic value of ctDNA or CTCs in only one type of gene mutation. 59, 71, 72 This is the first comprehensive study to analyze the diagnostic value of both ctDNA and CTCs for various gene mutations in lung cancer. We found that ctDNA might have better diagnostic performance than CTCs; however, clinical application of ctDNA for genemutation detection in lung cancer still needs to consider cost, operation process, and other factors. Meanwhile, subgroup analyses based on detailed EGFR-mutation subtypes, the detection methods of CTCs or ctDNA, and consistency of detection methods between liquid biopsy and tissue biopsy, were also carried out to explore potential influencing factors. However, other gene mutations in lung cancer, such as PIK3CA and TP53, were not included in our study, due to limited literature, which is the subjects of further investigations.
Conclusion
For lung cancer, ctDNA showed equivalent diagnostic ability as CTCs when detecting EGFR and its subtypes, and excellent performance for KRAS-and ALK-mutation detection. In general, ctDNA might be more suitable for clinical application of gene-mutation detection in lung cancer. Furthermore, our study also implies the significance of effective extraction kits and detection methods for improving the diagnostic capacity of ctDNA and CTCs. 
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